BGMS

#4898
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.86
0.86
Jahresspanne
0.57
6.70
Tagesänderung
-3.37%
Monatliche Änderung
-2.27%
6 month change
-10.06%
Jahresänderung
-85.67%
Vorheriger Schlusskurs
0.8 9
Open
0.8 6
Tief
0.8 6
Hoch
0.8 6
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q4 FY2018

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. on October 4, 2018, reporting events occurring on October 1, 2018. The filing details the entry into a Clinical Collaboration Agreement (CCA) with The University of Texas MD Anderson Cancer Center to evaluate the safety and efficacy of three company medicines in patients with hematological malignancies.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a material definitive agreement rather than periodic financial performance.

Material Changes and Agreement Details

  • Agreement: Clinical Collaboration Agreement (CCA) with MD Anderson.
  • Scope: Four clinical studies with a total projected enrollment of up to 170 patients.
  • Compounds: Studies will evaluate CYC065, CYC140, and sapacitabine as single agents or in combination with approved drugs.
  • Specific Protocols:
    • Phase 1b trial of CYC065 combined with venetoclax for relapsed/refractory CLL (IRB approved).
    • Phase 1 first-in-human evaluation of CYC140 for advanced leukemias or MDS (IRB approved).
    • Two additional protocols in development evaluating combinations of CYC065 and sapacitabine.
  • Roles: Cyclacel acts as the regulatory sponsor and provides investigational drugs; MD Anderson leads the studies and assumes patient costs.
  • Financial Terms: Cyclacel will make certain payments to MD Anderson upon the first commercial sale in specific indications studied. The agreement remains in effect for a three-year payment period.

Guidance, Outlook, and Risks

Management commentary is limited to the announcement of the collaboration. The filing notes that the full agreement text is filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2018, with portions omitted for confidential treatment. Termination rights exist for both parties in the event of a material breach that is not cured within 90 days of notice.

Investor Verification Checklist

  • Verify the specific payment obligations and milestones in the full CCA text filed as an exhibit to the Form 10-Q.
  • Confirm the status of the two protocols currently in development beyond the two IRB-approved studies.
  • Review the company's cash position to ensure sufficient liquidity to fund the investigational drug supply and regulatory filings required under the agreement.
  • Monitor the initiation dates for the Phase 1b and Phase 1 trials to assess development timeline adherence.